ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 373

The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data

Maja Spiritovic1,2, Sabina Oreska2,3, Hana Storkanova2,3, Barbora Hermankova1,2, Petr Cesak4, Adela Rathouska2, Katerina Kubinova2,3, Martin Klein2,3, Lucia Vernerova2,3, Olga Ruzickova2,5, Herman F Mann2,6, Karel Pavelka2,3, Ladislav Šenolt2,3, Jiri Vencovsky2,7 and Michal Tomcik2,3, 1Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 3Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Body Composition Laboratory, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 6First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 7Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: dermatomyositis, exercise, Idiopathic Inflammatory Myopathies (IIM), polymyositis and rehabilitation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Muscle Biology, Myositis and Myopathies Poster I: Clinical Features and Disease Course

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Muscle inflammation and weakness, subsequent atrophy and permanent muscle damage in idiopathic inflammatory myopathies (IIM) lead to impaired function, reduced muscle strength, endurance and aerobic capacity, decreasing quality of life. Data on the effectiveness of non-pharmacological care in IIM are limited due to heterogeneity of studied interventions/outcomes. The aim of our study was to minimalize the limitations of available studies and to determine the effect of an intensive exercise program on muscle strength and endurance and the quality of life in cohorts with a substantial number of IIM patients.

Methods: All patients were non-selectively consecutively recruited into intervention (IG) and control (CG) group and they had impaired skeletal muscle strength. They fulfilled the Bohan and Peter 1975 diagnostic criteria. Patients from both groups received educational material for home exercises, but only the IG underwent a six-month intensive ADL (activities of daily living) and muscle strength exercise program with a subsequent six-month follow-up period. All patients were evaluated by a physician and physiotherapist blinded to intervention at 0, 3, 6 and 12 months. Patients also filled out patient reported outcomes/questionnaires and provided blood for routine laboratory analysis and biobanking. Data analysis was performed between groups and within the group.

Results: In total 27 patients were included in the IG and 23 patients in the CG. Compared to the observed statistically significant deterioration in the CG over the period of 0-6 months, we found a statistically significant improvement in IG in objectively assessed muscle strength and endurance as well as in subjectively assessed functional abilities (HAQ) and depression (BDI-II). During the follow-up period, there was a significant deterioration or stagnation of the achieved results in the IG. However, improved functional abilities during the intervention period persisted in the IG even in the follow-up period. Only numerical improvements in the IG compared to numerical deterioration in CG, that did not achieve statistical significance, during the intervention period, were observed in some subjectively assessed patient reported outcomes assessing quality of life and fatigue.

Conclusion: Our program led to a significant improvement in the observed parameters that was clinically significant in a substantial proportion of patients (in the IG) and prevention of the expected worsening in muscle strength and endurance (observed in the CG).

Acknowledgments: The project was supported by AZV-16-33574A, SVV for FTVS UK 2019-260466, MHCR 023728

Parameter

(unit)

Intervention group

Mean ± SEM

Control group

Mean ± SEM

Intra-group analysis (Friedman+Dunn)

Inter-group analysis (2WA)

Interevention gr.

Control group

MMT8

m0: 54.7 ± 2.6

m0: 63.6 ± 2.0

m0-3: p<0.01

m0-3: p<0.05

p<0.0001

m3: 60.7 ± 2.4

m3: 57.9 ± 1.8

m3-6: p<0.0001

m3-6: NS

m6: 69.1 ± 1.9

m6: 54.2 ± 1.9

m0-6: p<0.0001

m0-6: p<0.0001

m12: 64.0 ± 2.5

m12: 56.5 ± 2.2

m6-12: p<0.05

m6-12:NS

FI-2 (%)

m0: 30.0 ± 4.4

m0: 38.3 ± 5.3

m0-3: p<0.01

m0-3: NS

p<0.0001

m3: 46.9 ± 4.7

m3: 29.6 ± 4.6

m3-6: p<0.0001

m3-6: NS

m6: 70.6 ± 4.9

m6: 26.1 ± 4.1

m0-6: p<0.0001

m0-6: p<0.01

m12: 58.4 ± 5.8

m12: 25.7 ± 3.6

m6-12: p<0.05

m6-12: NS

HAQ

m0: 0.9 ± 0.2

m0: 1.3 ± 0.2

m0-3: NS

m0-3: NS

p=0.0002

m3: 0.7 ± 0.1

m3: 1.4 ± 0.2

m3-6: NS

m3-6: NS

m6: 0.6 ± 0.1

m6: 1.4 ± 0.2

m0-6: p<0.01

m0-6: NS

m12: 0.8 ± 0.2

m12: 1.5 ± 0.2

m6-12: p<0.05

m6-12: NS

BDI-II

m0: 11.9 ± 2.1

m0: 13.0 ± 1.4

m0-3: NS

m0-3: NS

p=0.0025

m3: 10.7 ± 1.7

m3: 14.3 ± 1.7

m3-6: NS

m3-6: NS

m6: 8.9 ± 1.5

m6: 15.7 ± 1.

m0-6: p<0.05

m0-6: NS

m12: 10.5 ± 2.0

m12: 16.0 ± 2.0

m6-12: NS

m6-12: NS

Acronyms: SEM, standard error of the mean; Friedman, Friedman’s test; Dunn, Dunn’s post hoc test; 2WA, two way ANOVA, MMT-8, Manual muscle test-8; FI-2, Functional index-2; HAQ, Health assessment questionnaire; BDI-II, Beck’s depression inventory-II; m0, month 0 (= at the baseline); m3, month 3 (= in the middle of the intervention period); m6, month 6 (= at the end of intervention); m12, month 12 (= at the end of a 6-month follow up period); p, p-value; NS, not significant


Disclosure: M. Spiritovic, None; S. Oreska, None; H. Storkanova, None; B. Hermankova, None; P. Cesak, None; A. Rathouska, None; K. Kubinova, None; M. Klein, None; L. Vernerova, None; O. Ruzickova, None; H. F. Mann, None; K. Pavelka, None; L. Šenolt, None; J. Vencovsky, None; M. Tomcik, None.

To cite this abstract in AMA style:

Spiritovic M, Oreska S, Storkanova H, Hermankova B, Cesak P, Rathouska A, Kubinova K, Klein M, Vernerova L, Ruzickova O, Mann HF, Pavelka K, Šenolt L, Vencovsky J, Tomcik M. The Effect of an Intensive Controlled 6-Moth Exercise Program with Subsequent 6-Month Follow-up Period in Patients with Idiopathic Inflammatory Myopathies – Preliminary Data [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/the-effect-of-an-intensive-controlled-6-moth-exercise-program-with-subsequent-6-month-follow-up-period-in-patients-with-idiopathic-inflammatory-myopathies-preliminary-data/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-effect-of-an-intensive-controlled-6-moth-exercise-program-with-subsequent-6-month-follow-up-period-in-patients-with-idiopathic-inflammatory-myopathies-preliminary-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology